Osteoarthritis (OA) is the most common joint disorder worldwide, characterized by progressive cartilage degradation, subchondral bone changes, synovitis, and chronic pain. Conventional management — NSAIDs, corticosteroids, hyaluronic acid injections — provides symptom relief but does not stop or reverse cartilage loss. MSC therapy is the most studied regenerative approach for OA, with a growing body of controlled clinical trial data.
Why Cartilage Makes MSCs Relevant
Cartilage is avascular — it has no blood supply, and therefore very limited capacity for self-repair. MSCs address this in two ways: (1) they secrete anti-inflammatory cytokines that reduce synovitis and slow cartilage degradation, and (2) they can differentiate into chondrocytes (cartilage cells) and contribute directly to tissue repair, particularly when delivered via intra-articular injection.
The Clinical Evidence Base
Randomized Controlled Trials
Multiple RCTs have compared intra-articular MSC injection to saline control or hyaluronic acid in knee OA. A 2019 Stem Cells study found significantly greater reductions in VAS pain scores and WOMAC function scores in MSC-treated patients at 12 months, with MRI-confirmed cartilage regeneration in a subset.
Long-Term Data
A 5-year follow-up study published in 2021 found that OA patients treated with allogeneic MSCs maintained improved pain and function scores versus baseline, with some patients showing stable or improved cartilage thickness on MRI. These are not outcomes achievable with corticosteroid or hyaluronic acid injections.
Delivery: Why Intra-Articular Matters
For OA, delivery method is important. IV infusion alone provides systemic anti-inflammatory effects but limited local cartilage benefit. Intra-articular injection delivers MSCs directly into the joint space, where they can interact with the cartilage and synovial environment most effectively. Our protocols typically combine both routes for systemic and local effect.
Which Joints Respond Best?
Knee OA has the largest evidence base and tends to show the most consistent clinical response. Hip OA data are more limited but positive. Shoulder, ankle, and finger OA protocols are based on the same mechanism and are used at True Regen Medical, though with less robust comparative data. Your physician will be explicit about the evidence level for your specific joint on your evaluation call.
Who Is Not a Good Candidate
Patients with Kellgren-Lawrence Grade 4 OA (bone-on-bone, complete cartilage loss) are unlikely to benefit significantly from MSC therapy — there is no remaining cartilage structure for regeneration to build on. We tell this to patients honestly, and in those cases we discuss whether systemic anti-inflammatory benefits alone justify treatment given their overall picture.